:strip_icc():format(jpeg)/kly-media-production/medias/5404248/original/071967200_1762400255-Foto_bersama_para_pembicara_dan_panelis.jpg)
“`html
Dengue Hemorrhagic Fever Cases Rise in Indonesia,BPJS Health Prepares for Increased Burden and Zero-Death Goal
Table of Contents
Published: November 2,2024 | Last Updated: November 2,2024
Indonesia is facing a concerning rise in dengue hemorrhagic fever (DHF) cases,prompting BPJS Health,the national health insurance provider,to prepare for a significant increase in financial burdens and strengthen its guarantee system. The institution aims to achieve zero deaths from dengue by 2030.
Data Discrepancies Between Ministry of Health and BPJS Health
Lily, a representative from BPJS Health, recently revealed that differing costs associated with treating primary versus secondary dengue infections are contributing to discrepancies in data reported by the Indonesian Ministry of Health and BPJS Health itself.
“At the health facility, a diagnosis of dengue – whether primary or secondary, especially secondary – will promptly increase the claim costs that we have to pay. So, is this an incentive? like that?” Lily stated. “Yes, so we will have different data later.”
The distinction is crucial as secondary dengue infections, occurring in individuals previously infected, tend to be more severe and require more intensive (and costly) care.
Increasing Dengue Cases and Financial Strain
BPJS Health data indicates a consistent increase in dengue fever claims from 2020 to 2024.this trend is projected to continue, placing a greater strain on the JKN (jaminan Kesehatan Nasional) financing system.
Based on data available as of August 2024, BPJS Health estimates 744,000 dengue cases. This figure is expected to rise, approaching the 1.5 million cases recorded in 2024.
The financial impact is substantial. In 2020, BPJS Health paid out IDR 31.2 trillion in dengue-related claims. This figure surged to IDR 2.9 trillion in 2024, and projections for 2025 suggest an even higher expenditure.
BPJS Health’s Response and Zero-Death Goal
Recognizing the escalating situation, BPJS Health is actively preparing to strengthen its guarantee system to accommodate the increasing demand for dengue treatment. The organization’s long-term goal is to eliminate dengue-related deaths in Indonesia by 2030.
Specific strategies for achieving this goal were not detailed in the available information, but likely include improved access to care, enhanced diagnostic capabilities, and potentially, support for preventative measures like mosquito control programs.
Background: Dengue fever is a mosquito-borne viral infection prevalent in tropical and subtropical regions, including Indonesia. The disease ranges in severity from a mild fever to severe dengue, which can be life-threatening.Indonesia’s geographic location and climate contribute to its high risk of dengue transmission.
Trends: Globally, dengue incidence has been increasing in recent decades, driven by factors such as urbanization, climate change, and increased travel. Indonesia has consistently reported a significant number of dengue cases annually.
Context: the JKN is Indonesia’s universal health coverage scheme, aiming to provide affordable healthcare access to all citizens. The rising cost of dengue treatment poses a challenge to the financial sustainability of the JKN.
Frequently Asked Questions
- What is the difference between primary and secondary dengue fever?
- Primary dengue occurs in individuals infected with the virus for the first time. Secondary dengue occurs in individuals who have previously been infected with a different serotype of the dengue virus.Secondary infections are frequently enough more severe.
- What is BPJS Health?
- BPJS Health is the Indonesian national health insurance provider, responsible for administering the JKN (Jaminan Kesehatan Nasional) universal health coverage scheme.
- What is the JKN?
- JKN (Jaminan Kesehatan Nasional
